Unither Pharmaceuticals, has become a globally renowned company for the development and manufacturing of sterile unit-doses, non-sterile liquids, liquid sticks, solid and semi-solid medications for the pharmaceutical and generic drug industry. The company operates 6 manufacturing sites and 1 R&D center in France, USA and Brazil. Founded in 1993 from the takeover of a Sanofi facility, Unither Pharmaceuticals generates revenues of +250 M€ with a team of more than 1,200 professionals. The Group offers a comprehensive range of products and is the world largest player in blow-fill-seal (BFS) sterile unit-dose market. Unither has been the trusted partner of several medium to large pharmaceutical companies for many years thanks to its long-standing track record of quality, innovation and industrial excellence.
The transaction will be put before the Unither Work Council and is subject to the signing of a definitive agreement, as well as the approval of the relevant competition and regulatory authorities.
Edmond de Rothschild Corporate Finance
M&A: Christian Menard (Managing director, member of the board), Laure Klein (Vice-president), Arthur Pignot (Analyst), Mohamed Rtel Bennani (Analyst)